Avestar Capital’s CorMedix CRMD Stock Holding History

Avestar Capital’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$28K	–	314
2022 Q3	$28K	Hold	10,000	–	–	0.01%	274
2022 Q2	$40K	Buy	+10,000	New	+$37.2K	0.01%	282
2021 Q4	–	Sell	-10,000	Closed	-$47K	–	444
2021 Q3	$47K	Hold	10,000	–	–	0.01%	441
2021 Q2	$69K	Hold	10,000	–	–	0.01%	434
2021 Q1	$88K	Hold	10,000	–	–	0.02%	313
2020 Q4	$74K	Hold	10,000	–	–	0.02%	266
2020 Q3	$57K	Hold	10,000	–	–	0.02%	224
2020 Q2	$63K	Buy	+10,000	New	+$46.3K	0.03%	181

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Avestar Capital's CRMD Position: Q4 2022 in Review

Avestar Capital sold out of CorMedix (CRMD) in Q4 2022, closing a stake of 10,000 shares — an estimated $28K sold.

Avestar Capital first reported a position in CRMD in Q2 2020 and held it in 8 quarters. The position peaked at $88K in Q1 2021. 65 funds tracked by Wall St. Rank hold CRMD as of Q4 2022.

Avestar Capital reported no remaining CorMedix position as of Q4 2022 after selling out during the quarter.
Avestar Capital sold 10,000 CorMedix shares in Q4 2022, an estimated $28K.
Avestar Capital first reported a position in CorMedix in Q2 2020 and held it in 8 quarters.
Avestar Capital's CorMedix position peaked at $88K in Q1 2021.
65 funds tracked by Wall St. Rank held CorMedix as of Q4 2022.

Based on Avestar Capital's 13F filing for Q4 2022, filed 20 Jan 2023.